> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Asana Bio Proposes ASN002 Study in Atopic Dermatitis
- URL: https://www.fdaweb.com/asana-bio-proposes-asn002-study-in-atopic-dermatitis/
- Published: 2017-03-16T12:00:00.000Z
- Updated: 2026-09-14T22:11:59.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138216

FDA has accepted an Asana BioSciences IND for ASN002, a novel dual SYK-JAK inhibitor, for treating atopic dermatitis. In the submission, the company proposes a Phase I randomized, double-blind, placebo-controlled, multiple dose escalation study to evaluate the therapy’s safety and tolerability as well as preliminary efficacy in subjects with moderate to severe atopic dermatitis. ASN002 is also being evaluated in a Phase 1-2 clinical trial in patients with non-Hodgkin’s lymphoma and solid tumors.